Peter Max
- CEO Partner
Transaction Description
The rights issue would, if fully subscribed, provide Spermosens with approximately SEK 24 million before issue costs. The rights issue included a warrant with a subscription in January/February 2024, which, if fully subscribed, woud provide Spermosens with between 24 MSEK and 73 MSEK before issue costs. The rights issue was subscribed to 69 per cent with preferential rights and 31 per cent without. The rights issue was thus subscribed to a total of 100 percent including subscription commitments. No guarantee commitments were activated. Spermosens received approximately SEK 24.4 million before issue costs, which were estimated to amount to approximately SEK 5.6 million, of which approximately SEK 3.4 million relates to guarantee costs.
Contact Person
Company Description
Spermosen’s goal is to improve male fertility diagnosis and treatment through the introduction of breakthrough products. Spermosen’s first patented product, JUNO-Checked, measures the binding capacity between sperm and egg cells, which is a prerequisite for natural fertilisation. The results are expected to help physicians choose the appropriate treatment method, contributing to more successful IVF treatments, reduced suffering and improved quality of life. The WHO estimates that more than 48 million couples are affected by infertility, half of which are wholly or partly caused by a male factor.
Financial and strategic advisors
to high caliber growth companies
in pursuit of market leadership.
© 2025 Gemstone Capital – Designet af Aveo webmarketing